Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
An anti-CXCR2 antibody is a monoclonal antibody designed to target and inhibit the C-X-C motif chemokine receptor 2 (CXCR2), a G protein-coupled receptor primarily expressed on neutrophils. CXCR2 plays a critical role in the recruitment of neutrophils to sites of inflammation in response to chemokines such as CXCL1, CXCL2, and CXCL8 (IL-8). By blocking these interactions, anti-CXCR2 antibodies can reduce inflammatory cell infiltration and tissue damage. Preclinical research, including studies in mycoplasma superantigen-driven autoimmune arthritis models, has shown that targeting CXCR2, especially in combination with IL-17 inhibition, can significantly alleviate joint inflammation and disease progression by reducing leukocyte infiltration and the expression of pro-inflammatory chemokines in joint tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-CXCR2 antibody.